Your new experience awaits. Try the new design now and help us make it even better

BRIEF RESEARCH REPORT article

Front. Public Health

Sec. Radiation and Health

Volume 13 - 2025 | doi: 10.3389/fpubh.2025.1659275

Estimating Proton Beam Therapy Utilization and Investment in Thailand

Provisionally accepted
Imjai  ChitapanaruxImjai Chitapanarux1Ekkasit  TharavichitkulEkkasit Tharavichitkul1*Anussara  PrayongratAnussara Prayongrat2Patumrat  SripanPatumrat Sripan3Eduardo  ZubizarretaEduardo Zubizarreta4Yavuz  AnacakYavuz Anacak5Pathomphorn  SiraprapasiriPathomphorn Siraprapasiri6Tharathorn  TunkasamitTharathorn Tunkasamit7Chonsanee  ChangmaneeChonsanee Changmanee8
  • 1Chiang Mai University Division of Radiation Oncology, Chiang Mai, Thailand
  • 2King Chulalongkorn Memorial Hospital, Division of Radiation Oncology, Bangkok, Thailand
  • 3Chiang Mai University Research Institute for Health Sciences, Chiang Mai, Thailand
  • 4International Atomic Energy Agency Department of Management, Vienna, Austria
  • 5Ege University, Division of Radiation Oncology, Faculty of Medicine, Izmir, Türkiye
  • 6Thailand, Ministry of Public Health, Bangkok, Thailand
  • 7Udonthani Cancer Hospital, Udonthani, Thailand, Udonthani, Thailand
  • 8Department of Radiotherapy, Maha Vajiralongkorn Thanyaburi Hospital, Thailand, Prathumthani, Thailand

The final, formatted version of the article will be published soon.

Background: Thailand's first Proton Beam Therapy (PBT) center became operational in August 2021. Given the high costs and specialized expertise required, evaluating the clinical and economic implications of PBT and planning for its expansion are essential for Thailand's healthcare system. Methods: This study projected national PBT demand using data from the Thai PBT center, the Thai Association of Radiation Oncology (THASTRO), national cancer registry reports (Volumes VIII–X), and GLOBOCAN (2022–2040). The number of cancer patients requiring PBT was estimated based on: 1) Thailand's Comptroller General's Department (CGD) reimbursement guidelines (June 2023), and 2) the American Society for Radiation Oncology (ASTRO) model policy. Infrastructure, personnel, and cost data were collected, with resource gaps assessed using RRCC version 24. Results: Between 2022–2023, the first PBT center treated 628 patients—approximately 7% of all radiotherapy cases. Under CGD's limited reimbursement criteria, an estimated 1,454–2,797 patients per year would be eligible for PBT, corresponding to a need for 3–5 PBT units. However, when reimbursement constraints are excluded, this estimate increases to 6–10 units. The ASTRO model suggests even broader eligibility, with 4,471–5,430 patients requiring 10–20 units. The cost of a basic PBT unit is estimated at USD $30 million (excluding building infrastructure), with a treatment course costing approximately $38,000 (RRCC v.24). Conclusions: The gap between reimbursement-and need-based demand highlights the tension between clinical benefit and cost. Strategic planning must balance equitable access, financial sustainability, and future growth of PBT in Thailand.

Keywords: proton beam therapy, Estimation, utilization, Cancer, Thailand

Received: 03 Jul 2025; Accepted: 25 Aug 2025.

Copyright: © 2025 Chitapanarux, Tharavichitkul, Prayongrat, Sripan, Zubizarreta, Anacak, Siraprapasiri, Tunkasamit and Changmanee. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Ekkasit Tharavichitkul, Chiang Mai University Division of Radiation Oncology, Chiang Mai, Thailand

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.